Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further
Interviewed by Sisterhood editorial board member Daphne Zohar, Kate Haviland talks about the numerous programs that Blueprint created, the rationale behind key go/no-go and partnering decisions, and how she feels about the biotech sector today.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Biotech CEO Sisterhood
Former BIO CEO Rachel King describes her career and shares advice on what makes a successful biotech CEO
Katherine Stueland describes joining GeneDx as a first time CEO during a turbulent time and reshaping it into a leader in genetic testing for rare disease diagnosis
Amy Burroughs discusses the success of Terns Pharma and developing TERN-701 for CML, being acquired by Merck for $6.7 billion, and leadership learnings throughout her career
Fresh off of a successful IPO, Avalyn Pharma CEO Lyn Baranowski describes the company's inhaled medicines platform, and shares her secrets to success as a leader
Get summaries like this every morning.
Free AI-powered recaps of Biotech CEO Sisterhood and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.